Same Indication

Nivolumab vs Raltegravir

Nivolumab vs Raltegravir: Overview

This comparison examines the pharmacological differences between Nivolumab and Raltegravir.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Nivolumab — 27 days.

Chemical Properties

Type: Nivolumab — Antibody; Raltegravir — Small molecule.